To close the pediatric innovation gap, this biotech has to think differently

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

By Alexandra Pecci • Oct. 11, 2023

Google bets on AI in the life sciences as ‘technology for a purpose’

A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

By Alexandra Pecci • Oct. 10, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Research in space yields clues about boosting bone health on Earth

A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.

By Kelly Bilodeau • Oct. 10, 2023

A biotech ‘tuning’ the genome for a potentially safer gene therapy

Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

By Kelly Bilodeau • Oct. 9, 2023

Key upcoming events for pharma execs

Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

By Meagan Parrish • Oct. 6, 2023

FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

By Michael Gibney • Oct. 5, 2023

Where have all the unicorns gone? A look at 4 billion-dollar biotechs

Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.

By Alexandra Pecci • Oct. 3, 2023

5 FDA decisions to watch in the fourth quarter

The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.

By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023

The ALS therapy keeping the human pig heart transplant pumping

Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.

By Kelly Bilodeau • Oct. 2, 2023

3 recent FDA adcomm rejections — and why they matter

Decisions that could spell doom for drugs in development and already on the shelves.

By Meagan Parrish • Sept. 29, 2023

Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’

The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.

By Alexandra Pecci • Sept. 26, 2023

Three years after an FDA rejection, DBV sees a path for its peanut patch

Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

By Karissa Waddick • Sept. 22, 2023

What happened to ivermectin?

The saga of the anti-parasitic drug continues.

By Alexandra Pecci • Sept. 20, 2023

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

By Michael Gibney • Sept. 15, 2023

In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.

By Michael Gibney • Sept. 14, 2023

Catching up with 2022 PharmaVoice 100 honorees

Tapping into our growing community for expertise and inspiration.

By Meagan Parrish • Sept. 13, 2023

A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say

A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.

By Alexandra Pecci • Sept. 12, 2023

A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups

The biotech’s chief financial officer Robert Landry is retiring in February.

By Karissa Waddick • Sept. 12, 2023

Ex-Sanofi executive Sibold joins Madrigal as new CEO

Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.

By Ned Pagliarulo • Sept. 11, 2023

Immuneering takes aim at cancer’s ‘superhighway’

After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

By Kelly Bilodeau • Sept. 11, 2023

‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.

By Michael Gibney • Sept. 7, 2023

Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery

Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

By Alexandra Pecci • Sept. 6, 2023

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

By Meagan Parrish • Sept. 1, 2023

Lawmakers are already gunning for more dramatic drug pricing reforms

Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.

By Karissa Waddick • Aug. 31, 2023